Krawczyk Agata, Strzałka-Mrozik Barbara, Wcisło-Dziadecka Dominika, Grabarek Beniamin, Kimsa-Dudek Magdalena, Gola Joanna
Department of Nutrigenomics and Bromatology, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia in Katowice, Sosnowiec, Poland.
Department of Molecular Biology, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia in Katowice, Sosnowiec, Poland.
Dermatol Ther. 2020 May;33(3):e13277. doi: 10.1111/dth.13277. Epub 2020 Feb 28.
Biological drugs are an alternative to treatment of psoriasis and psoriatic arthritis. Adalimumab is a representative of the anti-TNF group. The underlying of this disease is a cellular homeostasis disorder-apoptosis. Many proteins are involved in the apoptosis induction pathways, including those from the BCL-2 family. The aim of the study was to perform a transcriptional analysis of the genes coding selected proteins from the BCL-2 family in patients treated with adalimumab therapy, and to determine the direction of these changes. The test materials were peripheral blood mononuclear cells. The cells were obtained from 20 patients with psoriatic arthritis who were being treated with adalimumab (study group) and 20 healthy volunteers (control). The gene expression profile was determined using the real-time quantitative reverse transcription polymerase chain reaction technique. Statistically significant changes were observed in the expression level of the BNIP3, BNIP3L, and BCL2L1 genes (p < .05) during a 24-month observation of therapy. We indicated that adalimumab therapy has an impact on the expression of the analyzed genes, which may constitute a new class of molecular markers for assessing the effectiveness of a therapy. It appears that the BNIP3L gene could be used as a potential diagnostic marker of psoriasis.
生物药物是治疗银屑病和银屑病关节炎的一种替代方法。阿达木单抗是抗TNF组的代表药物。这种疾病的根本原因是细胞稳态紊乱——细胞凋亡。许多蛋白质参与细胞凋亡诱导途径，包括来自BCL-2家族的蛋白质。本研究的目的是对接受阿达木单抗治疗的患者中编码BCL-2家族所选蛋白质的基因进行转录分析，并确定这些变化的方向。测试材料是外周血单核细胞。细胞取自20例接受阿达木单抗治疗的银屑病关节炎患者（研究组）和20名健康志愿者（对照组）。使用实时定量逆转录聚合酶链反应技术确定基因表达谱。在24个月的治疗观察期间，观察到BNIP3、BNIP3L和BCL2L1基因的表达水平有统计学意义的变化（p < 0.05）。我们指出，阿达木单抗治疗对所分析基因的表达有影响，这可能构成一类新的评估治疗效果的分子标志物。看来BNIP3L基因可作为银屑病的潜在诊断标志物。
